Levetiracetam Hexal

Levetiracetam, the active ingredient in Levetiracetam Hexal, is an anticonvulsant presented as an oral tablet for oral use. It is indicated for the treatment of partial‑onset seizures, primary generalized tonic‑clonic seizures, and myoclonic seizures in adolescents and adults.

GNH USA supplies Levetiracetam Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide, providing reliable sourcing and regulatory‑aligned distribution for the global epilepsy care market. The company adheres to stringent quality standards and offers comprehensive support to procurement teams.

Levetiracetam is employed in the management of several seizure types within the epilepsy spectrum, offering an oral therapeutic option for patients who require seizure control. - Partial seizures: reduces frequency and severity of focal onset seizures in patients with epilepsy. - Generalized tonic‑clonic seizures: helps control primary generalized convulsions, decreasing seizure duration and recurrence. - Myoclonic seizures: decreases occurrence of sudden, brief muscle jerks associated with juvenile myoclonic epilepsy. - Adjunct therapy: may be used as add‑on treatment when seizures are not adequately controlled by other antiepileptic drugs.

Levetiracetam may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness that may affect balance. - Fatigue: persistent feeling of tiredness or reduced energy during daily activities. - Headache: mild to moderate cranial pain that can be intermittent or continuous. - Irritability: increased mood swings, agitation, or reduced tolerance to stress.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling of face or throat, or difficulty breathing requiring immediate medical attention. - Stevens‑Johnson syndrome: rare, potentially life‑threatening skin blistering and mucosal involvement. - Suicidal thoughts: emergence of depressive symptoms, anxiety, or suicidal ideation that must be reported promptly. - Blood abnormalities: rare occurrences of leukopenia, thrombocytopenia, or anemia observed in laboratory tests.

When prescribing Levetiracetam, clinicians should consider several precautionary measures to ensure safe use. - Renal function: adjust dose in patients with impaired renal clearance. - Psychiatric history: monitor for mood changes, depression, or suicidal ideation. - Pregnancy: potential risks are unknown; weigh benefits against possible fetal exposure. - Concomitant CNS depressants: use caution as additive sedation may occur. - Discontinuation: taper gradually to avoid increased seizure frequency. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Levetiracetam may interact with other medicines; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma levels, decreasing efficacy. - Phenobarbital: can lower levetiracetam concentrations, risking breakthrough seizures.

Moderate Interactions (Monitor Closely): - Valproic acid: may increase levetiracetam levels modestly; monitor for side effects. - Opioids: additive CNS depression may enhance sedation. - Alcohol: combined use can intensify dizziness and drowsiness. - Other antiepileptics: synergistic effects may require dose adjustments.